Notable Upgrades: CyberArk Software (CYBR), Elizabeth Arden (RDEN), Netflix (NFLX), Cytokinetics (CYTK), Microchip Technology (MCHP)

CyberArk Software (CYBR) shares rallied 20% to $54.88 early Friday after Oppenheimer raised their CYBR target to $55 from $45, noting the Israel-based computer security company blew past Wall Street estimates for its 4Q’14 earnings. CyberArk reported adjusted fourth-quarter EPS of $0.21 on revenue of $36.3 million, up 81% year-over-year. Analysts were expecting 5 cents a share on revs of $26.9 million.

On valuation measures, CyberArk Software, Ltd. shares are currently priced at 275.76x this year’s forecasted earnings compared to the industry’s 24.24x earnings multiple. Ticker has a PEG and forward P/E ratio of 112.54 and 266.55, respectively. Price/Sales for the same period is 15.58 while EPS is $0.19. Currently there are 2 analysts that rate CYBR a ‘Buy’, 5 rate it a ‘Hold’. No  analysts rates it a ‘Sell’. CYBR has a current median Wall Street price target of $36.00 with a high target of $55.00.

In the past 52 weeks, shares have traded between a low of $22.12 and a high of $54.70. Shares are up 75.50% year-over-year, and 32% year-to-date.

Shares of Elizabeth Arden, Inc. (RDEN) are rising 4.5% to $16.39 this morning after the stock was upgraded to ‘Outperform’ from ‘Market Perform’ at BMO Capital.

Elizabeth Arden, Inc., currently valued at $488.90M, has a median Wall Street price target of $15.00 with a high target of $22.00. Approximately 59K shares have already changed hands, compared to the stock’s average daily volume of 249.34K.

In the past 52 weeks, shares of the beauty products company have traded between a low of $14.48 and a high of $37.69 with the 50-day MA and 200-day MA located at $17.43 and $17.71 levels, respectively. Additionally, shares of RDEN trade at a P/E ratio of -1.51 and have a Relative Strength Index (RSI) and MACD indicator of 51.34 and +0.52, respectively.

RDEN currently prints a one year loss of about 42%, and a year-to-date loss of around 27%.

Analysts at Janney are out with a report this morning raising Netflix, Inc‘s (NFLX) fair value to $500 with a ‘Buy’ rating.

NFLX shares are currently priced at 106.87x this year’s forecasted earnings, which makes them expensive compared to the industry’s 2.40x earnings multiple. Ticker has a forward P/E of 83.05 and t-12 price-to-sales ratio of 5.02. EPS for the same period is $4.32.

In the past 52 weeks, shares of Los Gatos, California-based Internet television network have traded between a low of $299.50 and a high of $489.29 and are now at $461.69. Shares are up 6.48% year-over-year, 33.70% year-to-date.

Shares of Cytokinetics, Incorporated (CYTK) rallied 20% on Friday after an upgrade to ‘Overweight’ from ‘Neutral’ at Piper Jaffray.

Cytokinetics Inc. on Thursday reported Q4 earnings of $8.4 million. The South San Francisco, Calif.-based biopharmaceutical firm said it had net income of $0.23 vs $0.17 estimate. Revs came in at $21.8 million in the period vs $11.63 million consensus.

CYTK shares recently gained $1.18 to $7.67. The stock is down more than 27% year-over-year and has lost roughly 19% year-to-date. In the past 52 weeks, Cytokinetics shares have traded between a low of $3.05 and a high of $13.26.

Cytokinetics, Incorporated closed Thursday at $6.49. The name has a total market cap of $280.78M.

Microchip Technology Inc. (MCHP) had its rating hiked to ‘Buy’ from ‘Hold’ by analysts at at Drexel Hamilton on Friday.

MCHP shares recently gained $0.42 to $50.40. In the past 52 weeks, shares of Chandler, Arizona-based manufacturer of semiconductor products for various embedded control apps have traded between a low of $36.92 and a high of $51.68. Shares are up 13.20% year-over-year, and 10.80% year-to-date.

Be the first to comment

Leave a Reply

Your email address will not be published.


*